Satellos wins FDA Fast Track for SAT-3247 in Duchenne muscular dystrophy

Satellos Bioscience Inc. announced on June 29, 2026 that the U.S. Food and Drug Administration granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy, adding to the drug's existing Orphan Drug and Rare Pediatric Disease designations.¹

Fast Track is intended to speed development and review of drugs for serious conditions with unmet medical needs, and companies with the designation may get more frequent FDA interactions, rolling review of marketing applications, and eligibility for Accelerated Approval and Priority Review if criteria are met.¹

SAT-3247 is currently being tested in the ongoing Phase 2 BASECAMP and TRAILHEAD studies in children and adults with Duchenne.¹ TRAILHEAD is an open-label study in adult participants, while BASECAMP is a global, randomized, placebo-controlled study in pediatric participants.¹ The company said additional data from these studies are expected in the second half of 2026, according to the release headline.

SAT-3247 is a proprietary, oral, small molecule candidate that Satellos is developing as a novel approach to regenerating skeletal muscle lost in Duchenne and other degenerative muscle conditions.¹ The drug targets AAK1, a protein regulator of muscle repair biology that Satellos says is disrupted in DMD, and works by inhibiting AAK1 to help restore a biochemical signal needed for repair, independent of dystrophin status.¹

CEO Frank Gleeson said the Fast Track designation "represents an important validation of SAT-3247" and reflects the company's commitment to Duchenne treatment, according to the release.